Alterations on the morphology, nitric oxide synthesis and activity of platelets reproduced in rats as possible biomarkers for depression are reversed by fluoxetine

Pharmacology Biochemistry and Behavior

Volumn 102, Issue 2, 2012, Pages 349-356

  González Trujano, María Eva ^a   Alvarado Vásquez, Noé ^b   Mendoza Sotelo, José ^a   López, Guadalupe ^a   Estrada Camarena, Erika ^a   Martínez Mota, Lucia ^a   Moreno, Julia ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Depression; Fluoxetine; Forced swimming test; Morphology; Nitric oxide; Platelets; Serotonin

Indexed keywords

BIOLOGICAL MARKER; FLUOXETINE; NITRIC OXIDE; SEROTONIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEPRESSION; FLOW CYTOMETRY; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; BLOOD PLATELETS; DEPRESSION; FLUOXETINE; MALE; MEMBRANE POTENTIALS; NITRIC OXIDE; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN;

ANIMALIA; RATTUS;

EID: 84861840357     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.03.012     Document Type: Article

References (69)

1. Alvarado-Vásquez N, Zapata E, Alcázar-Leyva S, Massó F, Montaño LF. Reduced NO synthesis and eNOS mRNA expression in endothelial cells from newborns with a strong family history of type 2 diabetes. Diabetes Metab Res Rev 2007a;23: 559-66.
2. Alvarado-Vásquez N, Páez A, Zapata E, Alcázar-Leyva S, Zenteno E, Massó F, et al. HUVECs from newborns with a strong family history of diabetes show diminished ROS synthesis in the presence of high glucose concentrations. Diabetes Metab Res Rev 2007b;23:71-80.
3. Anderson GM, Feibel FC, Cohen DJ. Determination of serotonin in whole blood, platelet-rich plasma, platelet-poor plasma and ultrafiltrate. Life Sci 1987;40:1063-70.
4. Annie-Jeyachristy S, Geetha A, Surendran R. Changes in the level of cytosolic calcium, nitric oxide and nitric oxide synthase activity during platelet aggregation: an in vitro study in platelets from normal subjects and those with cirrhosis. J Biosci 2008;33:45-53.
5. Aromaa A, Raitasalo R, Reunanen A, Impivaara O, Heliovaara M, Kneckt P, et al. Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl 1994;377:77-82.
6. Artigas F, Bel N, Casanovas JM, Romero L. Adaptative changes of the serotonergic system after antidepressant treatments. In: Filippini GA, et al, editor. Recent Advances in Tryptophan Research, 398. New York: Plenum Press; 1996. p. 51-9.
7. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93:1976-80.
8. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:37-151.
9. Bianchi M,Moser C, Lazzarini C, Vecchiato E, Crespi F. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res 2002;143:191-7.
10. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart 2002;88:521-3.
11. Cappelli-Bigazzi M, Battaglia C, Pannain S, Chiariello M, Ambrosio G. Role of oxidative metabolism on endothelium-dependent vascular relaxation of isolated vessels. J Mol Cell Cardiol 1997;29:871-9.
12. Carneiro AM, Blakely RD. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 2006;281:24769-80.
13. Castrén E, Võikar V, Rantamäki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007;7:18-21.
14. Cleare A. Reduced whole blood serotonin in major depression. Depress Anxiety 1997;5: 108-11.
15. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005;4:775-90.
16. Cryan JF, Lucki I. 5-HT4 receptors do not mediate the antidepressant-like behavioral effects of fluoxetine in a modified forced swim test. Eur J Pharmacol 2000;409:295-9.
17. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005a;29:547-69.
18. Cryan JF, PageME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 2005b;182:335-44.
19. Detke MJ, RickelsM, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995;121:66-72.
20. Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat FST model of depression. Exp Clin Psychopharmacol 1997;5:107-12.
21. Duman MLM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116-27.
22. Feighner JP, Boyer WF. Selective serotonin reuptake inhibitors. Chichester, England: John Wiley & Sons; 1996.
23. Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999;14:259-75.
24. Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the Precursors Study. Arch Intern Med 1998;158:1422-6.
25. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L, Baux G. Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 1999;93:597-603.
26. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-25.
27. Gigliucci V, Buckley KN, Nunan J, O'Shea K, Harkin A. A role for serotonin in the antidepressant activity of NG-nitro-L-arginine, in the rat forced swimming test. Pharmacol Biochem Behav 2010;94:524-33.
28. Gobbi G, Mirandola P, Tazzari PL, Ricci F, Caimi L, Cacchioli A, et al. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol 2003;121:892-6.
29. Gonzalez MB, Snyderman TB, Colket JT, Arias RM, Jiang JW, O'Connor CM, et al. Depression in patients with coronary artery disease. Depression 1996;4:57-62.
30. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003;44:616-23.
31. Harkin A, Connor TJ, Burns MP, Kelly JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004;14:274-81.
32. Hughes CW, Petty F, Sabri S, Gerald L, Kramer. Whole-blood serotonin in children and adolescents with mood and behaviour disorders. Psychiatry Res 1996;65:79-95.
33. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors. Nord J Psychiatry 1993;47(Suppl. 30):5-20.
34. Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1451-3.
35. Kaehler ST, Singewald N, Sinner C, Philippu A. Nitric oxide modulates the release of serotonin in the rat hypothalamus. Brain Res 1999;835:346-9.
36. Karege F, Widmer J, Bovier P, Gaillard JM. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. Neuropsychopharmacology 1994;10:207-14.
37. Kuhn DM, Arthur REJ. Inactivation of brain tryptophan hydroxylase by nitric oxide. J Neurochem 1996;67:1072-7.
38. Kuhn DM, Arthur Jr R. Molecular mechanism of the inactivation of tryptophan hydroxylase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. J Neurosci 1997;17:7245-51.
39. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Dev 2006;9:580-6.
40. Leaver HA, Schou AC, Rizzo MT, Prowse CV. Calcium-sensitive mitochondrial membrane potential in human platelets and intrinsic signals of cell death. Platelets 2006;17:368-77.
41. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1988;153:741-51.
42. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-22.
43. Mann JJ, Mcbride PA, Anderson GM, Mieczkowki TA. Platelet and whole blood serotonin content in depressed inpatients: correlationswith acute and life-time psychopathology. Biol Psychiatry 1992;32:243-57.
44. Martínez-Mota L, Estrada-Camarena E, López-Rubalcava C. Indorenate produces antidepressant-like actions in the rat forced swimming test via 5-HT1A receptors. Psychopharmacology (Berl) 2002;165:60-6.
45. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84.
46. Mendoza-Sotelo J, Torner C, Alvarado-Vásquez N, Lazo-Langner A, López G, Arango I, et al. Ultrastructural changes and immunolocalization of P-selectin in platelets frompatients with major depression. Psychiatry Res 2010;176:179-82.
47. Muck-Seler D, Jakovljevic M, Deanovic S. Platelet serotonin in subtypes of schizophrenia and unipolar depression. Psychiatry Res 1991;38:105-13.
48. Muck-Seler D, Jakovljevic M, Pivac N. Platelet 5-HT concentrations and suicidal behaviours in recurrent major depression. J Affect Disord 1996;39:73-80.
49. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000;140(4 Suppl.):57-62.
50. Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60:574-9.
51. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat FST. Psychopharmacology (Berl) 1999;147:162-7.
52. Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. South Med J 2008;101:612-7.
53. Paykel ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005;15:411-23.
54. Plante GE. Depression and cardiovascular disease: a reciprocal relationship. Metabolism 2005;54:45-8.
55. Pogun S, Kuhar MJ. Regulation of neurotransmitter reuptake by nitric oxide. Ann N Y Acad Sci 1994;738:305-15.
56. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2.
57. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-9.
58. Quintana J. Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic, and biological correlations. J Affect Disord 1992;24: 55-62.
59. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CH, Musselman DL, Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events. Circulation 2003;108:939-44.
60. Sheng JZ, Wang D, Braun AP. DAF-FM (4-amino-5-methylamino-2′, 7′-difluorofluorescein) diacetate detects impairment of agonist-stimulated nitric oxide synthesis by elevated glucose in human vascular endothelial cells: reversal by vitamin C and L-sepiapterin. J Pharmacol Exp Ther 2005;315:931-40.
61. Shi C, Guo K, Yew DT, Yao Z, Forster EL, Wang H, et al. Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets. Exp Gerontol 2008;6: 589-94.
62. Stahl SM, Ciaranello RD, Berger PA. Platelet serotonin in schizophrenia and depression. Adv Biochem Psychopharmacol 1982;34:183-98.
63. Tomasiak M, Stelmach H, Rusak T, Wysocka J. Nitric oxide and platelet energy metabolism. Acta Biochim Pol 2004;51:789-803.
64. Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003;23: 78-86.
65. Verhoeven AJ, Verhaar R, Gouwerok EG, De Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005;45:82-9.
66. Vignini A, Nanetti L,Moroni C, Testa R, Sirolla C,MarraM, et al. Platelet nitric oxide production and IR: relationwith obesity and hypertriglyceridemia. NutrMetab Cardiovasc Dis 2008;18:553-8.
67. Wang D, An SC, Zhang X. Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neurosci Lett 2008;433:59-64.
68. Wegener G, Volke V. Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals 2010;3:273-99.
69. Wegener G, Volke V, Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 2000;130: 575-80.